Hims's tirzepatide access has been directly affected by the industry-wide compounding regulatory shift — know the current state of what's actually offered before signing up, and budget for a separate membership fee on top of medication.
Luma Health's compounded tirzepatide is $297/month, flat, with no separate membership fee.
Hims & Hers is one of the largest telehealth brands in the country, and its weight-loss program has been through significant changes since 2025. Here's an honest, current-as-possible look at where things stand for tirzepatide specifically.
The Regulatory Backdrop That Matters Here
Following the FDA's determination that the tirzepatide shortage resolved in December 2024, and a September 2025 FDA warning letter to Hims over compounded semaglutide marketing claims, Hims faced a lawsuit from Novo Nordisk over its low-cost compounded semaglutide pill in early 2026. The companies reached a settlement making Hims an authorized distributor of Novo Nordisk's branded products instead. Confirm directly with Hims what compounded tirzepatide options, if any, are currently offered, since this regulatory environment has shifted availability across the industry broadly.
The Membership Fee Structure
Every Hims weight-loss patient pays a separate membership fee — commonly $39 for the first month, then $149/month on auto-renewal — on top of medication cost. This means a patient seeing "$149/month" advertised for medication should budget for a combined total closer to $298/month minimum once the membership fee is included.
The gap between advertised price and actual total cost is consistently the most cited complaint in Hims weight-loss reviews. Before enrolling, confirm explicitly whether the price you're seeing includes the membership fee or is medication cost alone.
What Reviews Generally Show
Hims holds a large volume of reviews with mixed results: positive feedback often centers on convenience and the brand's polish, while negative feedback concentrates on billing transparency, cancellation difficulty, and inconsistent provider continuity (some patients report being routed to different providers between visits). The BBB profile shows a pattern of complaints about unauthorized charges and refund timing.
A Simpler Alternative
If your priority is a clearly stated, all-inclusive price without a separate membership fee to track, Luma Health's compounded tirzepatide is $297/month flat — the number you see is the number you pay, with your medical evaluation, provider access, and shipping included.
Who Hims May Fit
- Want the recognizable brand and its broader health-services ecosystem
- Are comfortable confirming current medication availability directly given recent changes
- Budget for the full membership-plus-medication total upfront
- Want one clearly stated price with no separate membership fee
- Value pharmacy sourcing transparency
- Prefer consistent provider relationship continuity
One clear price,
no membership fee
Compounded tirzepatide at $297/month, flat — medical evaluation, provider visits, and shipping all included.
Get Started → Or start your free health assessmentFrequently Asked Questions
Availability has been directly affected by the 2025-2026 regulatory shift around compounded GLP-1s. Confirm current offerings directly with Hims, since this has changed meaningfully since 2025.
Add the membership fee ($39 first month, then $149/month) to whatever medication price is advertised — the minimum realistic monthly total is around $298.
Yes, Hims received an FDA warning letter in September 2025 over compounded semaglutide marketing claims, part of a broader industry-wide enforcement action.
Billing transparency (the gap between advertised and actual price), cancellation and refund difficulty, and inconsistent provider continuity between visits.
Yes. Flat-rate compounded providers like Luma Health price everything into one number ($297/month for tirzepatide) with no separate membership charge.
Yes, explicitly ask whether the advertised price includes the membership fee, given how consistently this specific confusion shows up in reviews.
References
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA.gov. 2025. FDA.gov
- Better Business Bureau. Hims & Hers Inc. complaint profile. BBB.org. 2026. BBB.org
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024